Jiangsu, China

Xiaoxing Huang


Average Co-Inventor Count = 5.3

ph-index = 1


Company Filing History:


Years Active: 2022-2025

where 'Filed Patents' based on already Granted Patents

2 patents (USPTO):

Title: Innovations and Contributions of Inventor Xiaoxing Huang

Introduction

Xiaoxing Huang is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of medicine, particularly in the development of innovative drug therapies. With a total of two patents to his name, Huang's work focuses on addressing critical health challenges.

Latest Patents

Huang's latest patents include the use of an anti-PD-1 antibody in combination with famitinib for treating tumors. This patent outlines a method that ensures controllable and tolerable toxicity while effectively reducing adverse reactions associated with the anti-PD-1 antibody. Another notable patent involves the use of a KOR agonist in combination with a MOR agonist for pain treatment. This innovative approach utilizes specific compounds to enhance therapeutic efficacy.

Career Highlights

Throughout his career, Xiaoxing Huang has worked with reputable companies such as Jiangsu Hengrui Medicine Company Ltd. and Suzhou Suncadia Biopharmaceuticals Co., Ltd. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Huang has collaborated with esteemed colleagues, including Lianshan Zhang and Changyong Yang. These partnerships have fostered a collaborative environment that promotes innovation and the advancement of medical science.

Conclusion

Xiaoxing Huang's contributions to the field of medicine through his patents and collaborations highlight his commitment to improving healthcare solutions. His innovative approaches continue to pave the way for future advancements in drug therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…